Free Trial
NASDAQ:AKRO

Akero Therapeutics (AKRO) Stock Price, News & Analysis

Akero Therapeutics logo
$49.23 +0.94 (+1.95%)
Closing price 04:00 PM Eastern
Extended Trading
$49.03 -0.20 (-0.41%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akero Therapeutics Stock (NASDAQ:AKRO)

Key Stats

Today's Range
$47.94
$49.48
50-Day Range
$47.49
$56.28
52-Week Range
$21.34
$58.40
Volume
802,546 shs
Average Volume
1.40 million shs
Market Capitalization
$3.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$81.57
Consensus Rating
Buy

Company Overview

Akero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

AKRO MarketRank™: 

Akero Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 210th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akero Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Akero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Akero Therapeutics is -24.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Akero Therapeutics is -24.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Akero Therapeutics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.92% of the float of Akero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akero Therapeutics has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Akero Therapeutics has recently decreased by 0.49%, indicating that investor sentiment is improving.
  • Dividend Yield

    Akero Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akero Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.92% of the float of Akero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akero Therapeutics has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Akero Therapeutics has recently decreased by 0.49%, indicating that investor sentiment is improving.
  • News Sentiment

    Akero Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Akero Therapeutics this week, compared to 7 articles on an average week.
  • MarketBeat Follows

    5 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,013,920.00 in company stock.

  • Percentage Held by Insiders

    Only 7.07% of the stock of Akero Therapeutics is held by insiders.

  • Read more about Akero Therapeutics' insider trading history.
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKRO Stock News Headlines

“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
Lifesci Capital Brokers Increase Earnings Estimates for AKRO
See More Headlines

AKRO Stock Analysis - Frequently Asked Questions

Akero Therapeutics' stock was trading at $27.82 on January 1st, 2025. Since then, AKRO stock has increased by 75.6% and is now trading at $48.8650.

Akero Therapeutics, Inc. (NASDAQ:AKRO) posted its earnings results on Friday, August, 8th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.11.

Akero Therapeutics (AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Top institutional investors of Akero Therapeutics include General Atlantic L.P. (7.17%), State Street Corp (3.43%), Bellevue Group AG (2.48%) and Alkeon Capital Management LLC (2.31%). Insiders that own company stock include Skorpios Trust, G Walmsley Graham, Andrew Cheng, Jonathan Young, Timothy Rolph, Seth Loring Harrison, Catriona Yale, William Richard White, Patrick Lamy, Scott A Gangloff and Tomas J Heyman.
View institutional ownership trends
.

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/08/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKRO
CIK
1744659
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$109.00
Low Price Target
$64.00
Potential Upside/Downside
+66.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$252.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-15.84%
Return on Assets
-14.59%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
12.66
Quick Ratio
12.66

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.82 per share
Price / Book
3.81

Miscellaneous

Outstanding Shares
79,989,000
Free Float
74,334,000
Market Cap
$3.91 billion
Optionable
Optionable
Beta
-0.28

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:AKRO) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners